Show simple item record

dc.contributor.authorMikov, M.
dc.contributor.authorÐanic, M.
dc.contributor.authorPavlovic, N.
dc.contributor.authorStanimirov, B.
dc.contributor.authorGolocorbin-Kon, S.
dc.contributor.authorStankov, K.
dc.contributor.authorAl-Salami, Hani
dc.date.accessioned2017-11-24T05:24:48Z
dc.date.available2017-11-24T05:24:48Z
dc.date.created2017-11-24T04:48:43Z
dc.date.issued2017
dc.identifier.citationMikov, M. and Ðanic, M. and Pavlovic, N. and Stanimirov, B. and Golocorbin-Kon, S. and Stankov, K. and Al-Salami, H. 2017. Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. European Journal of Drug Metabolism and Pharmacokinetics: pp. 1-12.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/58252
dc.identifier.doi10.1007/s13318-017-0441-y
dc.description.abstract

© 2017 Springer International Publishing AG A major advancement in therapy of type 1 diabetes mellitus (T1DM) is the discovery of new treatment which avoids and even replaces the absolute requirement for injected insulin. The need for multiple drug therapy of comorbidities associated with T1DM increases demand for developing novel therapeutic alternatives with new mechanisms of actions. Compared to other sulphonylurea drugs used in the treatment of type 2 diabetes mellitus, gliclazide exhibits a pleiotropic action outside pancreatic ß cells, the so-called extrapancreatic effects, such as antiinflammatory and cellular protective effects, which might be beneficial in the treatment of T1DM. Results from in vivo experiments confirmed the positive effects of gliclazide in T1DM that are even more pronounced when combined with other hypoglycaemic agents such as probiotics and bile acids. Even though the exact mechanism of interaction at the molecular level is still unknown, there is a clear synergistic effect between gliclazide, bile acids and probiotics illustrated by the reduction of blood glucose levels and improvement of diabetic complications. Therefore, the manipulation of bile acid pool and intestinal microbiota composition in combination with old drug gliclazide could be a novel therapeutic approach for patients with T1DM.

dc.publisherSpringer France
dc.titlePotential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics
dc.typeJournal Article
dcterms.source.startPage1
dcterms.source.endPage12
dcterms.source.issn0378-7966
dcterms.source.titleEuropean Journal of Drug Metabolism and Pharmacokinetics
curtin.departmentSchool of Pharmacy
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record